Abrilumab

Drug Profile

Abrilumab

Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis

Most Recent Events

  • 28 Jul 2015 Phase-II development in Crohn's disease and Ulcerative colitis is ongoing worldwide
  • 19 Jun 2015 Amgen completes enrolment in its phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)
  • 19 Jun 2015 Amgen completes enrolment in its phase II trial for Ulcerative colitis in USA, Canada, Australia, European Union, Norway, Switzerland and Russia (NCT01694485)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top